Effects of Acetazolamide on Sleep Disordered Breathing in Pulmonary Vascular Disease: a Randomised Controlled Trial

Overview

Journal ERJ Open Res

Specialty Pulmonary Medicine

Date 2024 Oct 29

PMID 39469274

Authors

Esther I Schwarz

Stephanie Saxer

Mona Lichtblau

Simon R Schneider

Julian Muller

Laura Mayer

Konrad E Bloch

Silvia Ulrich

Affiliations

Soon will be listed here.

Abstract

Background: Patients with pulmonary vascular disease (PVD) often suffer from nocturnal hypoxaemia, but also from sleep apnoea. Short-term use of acetazolamide increases ventilation due to metabolic acidosis and also reduces loop gain. We investigated whether prolonged use of acetazolamide improves sleep disordered breathing in PVD.

Methods: In a randomised controlled crossover trial, patients with PVD were randomly assigned to acetazolamide 250 mg and placebo twice daily for 5 weeks. Patients underwent respiratory polygraphy at baseline and at the end of each intervention phase. Outcomes of interest were the effect of acetazolamide on mean nocturnal oxygen saturation ( ), time with oxygen saturation <90% ( ), apnoea-hypopnoea index (AHI) and sleep apnoea severity.

Results: In 20 patients with PVD (55% women, nine with pulmonary arterial hypertension, 11 with distal chronic thromboembolic pulmonary hypertension; mean±sd nocturnal 88.8±3.5%, obstructive AHI 12.6±12.3 events·h), 5 weeks of acetazolamide resulted in a significant improvement in nocturnal oxygenation compared to placebo (mean nocturnal +2.3% (95% CI 1.3-3.3%); p<0.001 and -18.8% (95% CI -29.6- -8.0%); p=0.001). Acetazolamide increased the proportion of patients with mean nocturnal ≥90% from 45% to 85%. The percentage of patients with AHI >5 events·h was reduced from 75% to 60% and with AHI >15 events·h from 30% to 15%. Two patients discontinued the study because of mild side-effects.

Conclusions: Acetazolamide given for 5 weeks reduces nocturnal hypoxaemia in PVD to a clinically relevant level and reduces the proportion of patients with obstructive sleep apnoea.

References

Minic M, Granton J, Ryan C . Sleep disordered breathing in group 1 pulmonary arterial hypertension. J Clin Sleep Med. 2014; 10(3):277-83. PMC: 3927433. DOI: 10.5664/jcsm.3528. View

Schulz K, Altman D, Moher D . CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010; 340:c332. PMC: 2844940. DOI: 10.1136/bmj.c332. View

Schulz R, Baseler G, Ghofrani H, Grimminger F, Olschewski H, Seeger W . Nocturnal periodic breathing in primary pulmonary hypertension. Eur Respir J. 2002; 19(4):658-63. DOI: 10.1183/09031936.02.00225102. View

Ulrich S, Keusch S, Hildenbrand F, Lo Cascio C, Huber L, Tanner F . Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with pre-capillary pulmonary hypertension and sleep-disturbed breathing: randomized, double-blind, cross-over trial. Eur Heart J. 2013; 36(10):615-23. DOI: 10.1093/eurheartj/eht540. View

Carta A, Lichtblau M, Berlier C, Saxer S, Schneider S, Schwarz E . The Impact of Breathing Hypoxic Gas and Oxygen on Pulmonary Hemodynamics in Patients With Pulmonary Hypertension. Front Med (Lausanne). 2022; 9:791423. PMC: 8878983. DOI: 10.3389/fmed.2022.791423. View

Javaheri S, Badr M . Central sleep apnea: pathophysiologic classification. Sleep. 2022; 46(3). PMC: 9995798. DOI: 10.1093/sleep/zsac113. View

Ulrich S, Fischler M, Speich R, Bloch K . Sleep-related breathing disorders in patients with pulmonary hypertension. Chest. 2008; 133(6):1375-1380. DOI: 10.1378/chest.07-3035. View

Carberry J, Amatoury J, Eckert D . Personalized Management Approach for OSA. Chest. 2017; 153(3):744-755. DOI: 10.1016/j.chest.2017.06.011. View

Jilwan F, Escourrou P, Garcia G, Jais X, Humbert M, Roisman G . High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest. 2012; 143(1):47-55. DOI: 10.1378/chest.11-3124. View

10.

Lichtblau M, Saxer S, Muller J, Appenzeller P, Berlier C, Schneider S . Effect of 5 weeks of oral acetazolamide on patients with pulmonary vascular disease: A randomized, double-blind, cross-over trial. Pulmonology. 2023; 30(4):362-369. DOI: 10.1016/j.pulmoe.2022.11.004. View

11.

Ulrich S, Saxer S, Hasler E, Schwarz E, Schneider S, Furian M . Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomised, placebo-controlled trial. Eur Respir J. 2019; 54(2). DOI: 10.1183/13993003.002762019. View

12.

Farber H, Badesch D, Benza R, Elliott C, Frantz R, McGoon M . Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. J Heart Lung Transplant. 2018; 37(8):948-955. DOI: 10.1016/j.healun.2018.03.010. View

13.

Schlatzer C, Schwarz E, Sievi N, Clarenbach C, Gaisl T, Haegeli L . Intrathoracic pressure swings induced by simulated obstructive sleep apnoea promote arrhythmias in paroxysmal atrial fibrillation. Europace. 2015; 18(1):64-70. DOI: 10.1093/europace/euv122. View

14.

Berry R, Budhiraja R, Gottlieb D, Gozal D, Iber C, Kapur V . Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2012; 8(5):597-619. PMC: 3459210. DOI: 10.5664/jcsm.2172. View

15.

Dumitrascu R, Tiede H, Eckermann J, Mayer K, Reichenberger F, Ghofrani H . Sleep apnea in precapillary pulmonary hypertension. Sleep Med. 2013; 14(3):247-51. DOI: 10.1016/j.sleep.2012.11.013. View

16.

Sands S, Collet J, Gell L, Calianese N, Hess L, Vena D . Combination pharmacological therapy targeting multiple mechanisms of sleep apnoea: a randomised controlled cross-over trial. Thorax. 2024; 79(3):259-268. DOI: 10.1136/thorax-2023-220184. View

17.

Schmickl C, Landry S, Orr J, Chin K, Murase K, Verbraecken J . Acetazolamide for OSA and Central Sleep Apnea: A Comprehensive Systematic Review and Meta-Analysis. Chest. 2020; 158(6):2632-2645. PMC: 7768933. DOI: 10.1016/j.chest.2020.06.078. View

18.

Nagaoka M, Goda A, Takeuchi K, Kikuchi H, Finger M, Inami T . Nocturnal Hypoxemia, But Not Sleep Apnea, Is Associated With a Poor Prognosis in Patients With Pulmonary Arterial Hypertension. Circ J. 2018; 82(12):3076-3081. DOI: 10.1253/circj.CJ-18-0636. View

19.

Tiede H, Rorzyczka J, Dumitrascu R, Belly M, Reichenberger F, Ghofrani H . Poor sleep quality is associated with exercise limitation in precapillary pulmonary hypertension. BMC Pulm Med. 2015; 15:11. PMC: 4342878. DOI: 10.1186/s12890-015-0005-3. View

20.

Schumacher D, Muller-Mottet S, Hasler E, Hildenbrand F, Keusch S, Speich R . Effect of oxygen and acetazolamide on nocturnal cardiac conduction, repolarization, and arrhythmias in precapillary pulmonary hypertension and sleep-disturbed breathing. Chest. 2014; 146(5):1226-1236. DOI: 10.1378/chest.14-0495. View